抗结核病药物短程化疗致肝功能损害180例  

Liver Damage Caused by Short-period Antituberculotic Chemical Treatment in 180 Cases

作　　者：邹公民[1] 覃兆科[1] 

机构地区：[1]湖北省荆州市第二人民医院,湖北荆州434000

出　　处：《中国药业》2007年第15期50-51,共2页China Pharmaceuticals

摘　　要：目的观察抗结核药物短程化疗对肝功能的损害情况。方法180例初治肺结核患者在SHRZ方案化疗中不分年龄,不分痰涂阴阳,入院时肝功能正常,均列入短程化疗组,观察丙氨酸氨基转移酶(ALT)与天门冬氨酸氨基转移酶(AST)的变化情况。结果化疗中肝损伤率达41.11%,其中患者受损比例乙型肝炎病毒标志物(HBVM)阳性组为59.25%,HBVM阴性组为32.75%(P<0.05);肝功能受损男性占51.43%,女性占9.54%(P<0.01)。结论制订化疗方案之前应了解病史,特别是与肝脏受损程度有关的疾病,以便短程化疗能顺利完成。Objective To observe the liver damage by antitubereulotic in the short-period treatment. Methods In the SHRZ chemical treatment, the 180 first-treating patients with pulmonary tuberculosis and normal liver function were put into the observing group of the short- period chemical treatment regardless of their ages and amount of expectoration. The changes of ALl＂ and AST were observed. Results In the chemical treatment, the rate of liver damage reached 41.11%. In it, the rate of liver damage was 59. 25% for the patients whose HBVM was positive and that was 32.75% for the patients whose HBVM was negative （P 〈0. 05）, and the rate of liver damage for male was 51.43% and that for female was 9.54% （P〈0.01）.Conciusion Before taking the chemical treatment, learning the medical history of patients, especially about the liver diseases, can guarantee the short-period treatment successfully.

关 键 词：乙型肝炎病毒标志物 肺结核 短程化疗 抗结核药物 肝损伤 

分 类 号：R969.3[医药卫生—药理学] R978.3[医药卫生—药学]